Vendor Intelligence Report: Peptide-S

Published 12 Jun 2026. 25-page investigative report on who is behind Peptide-S: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 128 Finnrick lab tests, Peptide-S posts 87 pass / 37 fail — an overall pass rate of 68%. The record is sharply product-specific rather than uniformly bad. GHK-Cu and Tirzepatide are the relative bright spots, while Retatrutide carries the larger warning signal, including reported 0.0 mg vials, and BPC-157 includes another reported 0.0 mg identity failure. The full report also shows why ratings compress under stricter grading, so a simple “tested fine” claim is not enough for this vendor.

The identity layer is thinner than the storefront suggests. Domain records place peptide-s.shop in late 2024 behind NameSilo/PrivacyGuardian masking, with archived storefront activity beginning a few months later; forum evidence repeatedly ties the operation to Jenny He, but the report does not find a verified legal company or manufacturer record behind the seller. That distinction matters when product, shipment, or refund disputes need an accountable counterparty.

The technical and operational findings add another dimension: Peptide-S is linked in page-source/API evidence to the Shop910 stack, a Putian platform reported to market special-goods, AB redirect and cloaking capabilities. A forum-attributed Chicago seizure tied to counterfeit postage, a brand-confusion/copycat lead around Changan Sheng, and one undisclosed Reddit tracking link make this a vendor where product selection, channel verification and batch-level evidence carry more weight than reputation alone.

Inside the full report:

  • Product-specific Finnrick pass/fail interpretation, methodology-divergence charts and the complete Appendix A laboratory table for all 11 products
  • RDAP, DNS and Wayback exhibits tracing the December 2024 domain registration, Cloudflare masking and early storefront captures
  • Operator-attribution analysis covering Jenny He, Changan District Sheng Peptide Trading, Saiwante, Sivnt and the unresolved Lipo C lead
  • Shop910 infrastructure analysis, including the evidence for special-goods positioning and cloaking/AB-redirect exposure
  • Fulfillment and reputation evidence covering the counterfeit-postage incident, partial-order complaints, copycat risk and affiliate-tracking scan

Risk assessment

  • Product-quality risk in weak Peptide-S lines — high: Retatrutide, BPC-157, Tesamorelin, Sermorelin and Cagrilintide show materially weak Finnrick records, including reported 0.0 mg vials for Retatrutide and BPC-157.
  • Identity and accountability opacity — high: No verified legal entity was found; the domain is privacy-proxied and the Jenny He attribution is forum-derived rather than filing-derived.
  • Cloaked gray-market infrastructure risk — high: Page-source/API evidence links Peptide-S to Shop910, a Putian SaaS platform reported to market special-goods, AB-redirect and cloak-system functionality.
  • Shipping and fulfillment integrity risk — medium: Forum testimony reports a March 2026 USPS counterfeit-postage seizure plus partial/missing-order disputes; independent postal records were not supplied.
  • Copycat and brand-confusion risk — medium: Changan Sheng/Bella copycat reports and no observed authorized-channel or COA-verification system make misdirection risk material.
  • Undisclosed affiliate-promotion risk — medium: One Reddit recommendation used tracking=GSP-1067 with no disclosure; broader X and coupon-site sweeps did not find a large network.